Risk factors for doxorubicin-induced congestive heart failure
about
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancerClinical heart failure in children, adolescents and young adults treated with anthracyclines and/or irradiation involving the heart regionTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerCardioprotective interventions for cancer patients receiving anthracyclinesTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerCardioprotective interventions for cancer patients receiving anthracyclinesAnthracyclines versus no anthracyclines for childhood cancerCardioprotective interventions for cancer patients receiving anthracyclinesDoxorubicin cardiomyopathyCardiotoxicity in childhood cancer survivors: strategies for prevention and managementCardio-oncology: Concepts and practiceIntegrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1Taxanes in the elderly patient with metastatic breast cancerChemotherapy-enhanced inflammation may lead to the failure of therapy and metastasisCardiac effects of anticancer therapy in the elderlyCardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelCancer survivors in the United States: a review of the literature and a call to actionSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsMitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specificCardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and ManagementPotential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer DrugsLong term side effects of adjuvant chemotherapy in patients with early breast cancerRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsLiposomes as nanomedical devicesTreatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancerEffects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivoCardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitroSignificance of adaptation mechanisms in adriamycin induced congestive heart failureScintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicityAmsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemiaPreclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicinChronic vascular toxicity of doxorubicin in an organ-cultured arteryDrug overdose--a hidden hazard of obesityEffect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicinNatriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphomaOverexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicityThe effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancerDoxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calciumDietary red palm oil protects the heart against the cytotoxic effects of anthracycline
P2860
Q24193790-F50FFCD9-3563-4864-A6D5-40DD81054CFDQ24200386-BE6BDA89-68FB-4633-867C-DA493E2F6509Q24234833-DC8E2BBE-8164-42B5-A190-55A340BE2703Q24236338-103BCA32-950C-40E1-8362-DFFD96F0F0A3Q24241602-E54E0FAB-89FB-4448-BD21-7866F4975C38Q24243021-C79AF3D7-DE95-4003-B205-E42F4465709CQ24244799-0F33A4A8-2C60-44F6-AD1E-9C32063F7E49Q24245027-6D5FA011-89A5-44F7-8C01-628B5051CFFBQ24606920-22990062-EC81-40E2-A71E-D6EA668DE28CQ24628695-D04472BF-5509-4CBA-A167-D0DD0063330CQ26750878-487428B5-9D07-41FD-9D8D-CD18DD099B6FQ26771931-02DE7FEA-55BE-48FD-9BDB-554E6BB80525Q26785458-A25B32FD-7169-4C60-92E6-11848923E7E1Q26858839-5202C11B-1F6B-43EB-894A-E03987217A90Q26863244-3DA9AF51-50B2-4596-A7ED-22D5E28D8856Q26864094-1889726A-93EE-4E8F-9128-6D8105A32C5FQ26865247-00373B06-26A1-441B-97F5-1FD9469230CCQ27007849-27C3DBAD-6FC4-4AD7-B02B-4F19537A5D4AQ27301261-10B97BE6-3C49-4685-BA61-8CBA7116FB86Q28068290-9C4B5FB5-723C-4FEE-936D-0C575990BFBAQ28070311-BBC7768D-3FAB-4E80-8FDC-AB8955F34E42Q28083233-0FF8E5C8-88D6-4BAD-9B6D-069016B1A905Q28087776-A487DF90-EF47-436F-A2AD-18999CDDB7DFQ28088315-A61E4C3A-525F-46E7-A2AC-1D1E3147188CQ28088408-1074AF7F-861E-4C08-AFE2-8688905EED3CQ28258783-E0CA42CA-C4A2-401E-9C83-5E8A12EB58C9Q28317674-DB6F05BF-0609-4B3B-B105-EA4CE8A25182Q28318119-DDEAAE7E-8690-4E89-8704-419DB7075CA4Q28326635-73479D8C-EF44-4ECA-A9A1-E8F89226A68DQ28327598-9DCFE46E-BAB0-4854-892C-BC1E7CFF505FQ28343576-E9706BD2-D2D9-46AA-B937-B659345A9CBEQ28361159-F9608B4C-B834-4401-9C03-9C955E03CF8AQ28362001-78B147C6-B76C-4905-80B9-0675D6B28DD9Q28366615-44FE003B-DC9A-4078-A656-7DF138D489F8Q28368331-1F175ABE-938C-415E-8418-7F46866ED432Q28370603-5403D9D5-D7E9-41C7-BE72-19810519C90DQ28379102-CC6080A4-5C54-436C-BA4B-586FC83F0C9EQ28540889-D6D70C2E-D72D-4B77-964A-AE8B911B5880Q28579647-1E1D9F7F-802F-425D-A59C-F6C9EA7A8279Q28583225-CC7CBD94-8B38-43BE-885D-2AE517527290
P2860
Risk factors for doxorubicin-induced congestive heart failure
description
1979 nî lūn-bûn
@nan
1979 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1979 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
name
Risk factors for doxorubicin-induced congestive heart failure
@ast
Risk factors for doxorubicin-induced congestive heart failure
@en
Risk factors for doxorubicin-induced congestive heart failure
@nl
type
label
Risk factors for doxorubicin-induced congestive heart failure
@ast
Risk factors for doxorubicin-induced congestive heart failure
@en
Risk factors for doxorubicin-induced congestive heart failure
@nl
prefLabel
Risk factors for doxorubicin-induced congestive heart failure
@ast
Risk factors for doxorubicin-induced congestive heart failure
@en
Risk factors for doxorubicin-induced congestive heart failure
@nl
P2093
P3181
P1476
Risk factors for doxorubicin-induced congestive heart failure
@en
P2093
A L Von Hoff
D D Von Hoff
F M Muggia
M Rozencweig
M W Layard
P3181
P356
10.7326/0003-4819-91-5-710
P407
P577
1979-11-01T00:00:00Z